AAGP® Research

See the promising research and results to date

In partnership with some of the world’s top researchers, ProtoKinetix has conducted more than a decade of laboratory testing throughout Europe and North America. Our proprietary anti-aging glycopeptide, AAGP®, has gone through a series of animal and human trials, and the results have been extremely promising. Learn about our research protocols and the potential we see for AAGP®.

Explore our research

See how AAGP® protects human islets against tacrolimus-related injury

icon-tests

Review AAGP®’s cytoprotective capacity and safety for islet transplantation

Find out where are today and where we are heading next.

icon-testcells

See the cells lines we’ve examined to uncover AAGP®’s potential.  

icon-tests

Review the results of our AAGP® dose and toxicity studies.

Learn how we’ve analyzed AAGP®’s concentration and potency.

Find out where are today and where we are heading next.

Dr. Kevin Gregory-Evans, lead macular researcher for ProtoKinetix, examines a specimen under a microscope.
A research assistant at The University of British Columbia takes a closer look at AAGP®-treated cells.
A vial containing an AAGP® solution is prepared for testing at The University of British Columbia.

What does the research show?

Cells protected by AAGP® were subjected to UVA, UVC, hydrogen peroxide, inflammatory (ILβ), time, temperature (-196°C, -80°C, -3°C, 3°C, 4°C, 15°C and 22°C) and low serum induced cell death at a pH of 5.3-10.5. The average increase in cell survival credited to AAGP® in the face of these conditions was over 55%. This cannot be attributed to AAGP® increasing cell proliferation as it has been found that AAGP® has no effect on cell doubling times in either Hela or fibroblast cells.
In addition to protecting cell survival, AAGP® has also been shown to preserve cell functionality. This has been tested not only with stem cell markers and CD34+ functionality tests but also in vivo studies where AAGP®-treated transplanted islet cells were found to reduce blood glucose concentrations in diabetic mice by 40% by day 40 in comparison to islet cells which were transplanted into mice without first being exposed to AAGP®.
  • Untreated
  • Treated

Research partners

Since 2005, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.

Create a secure online account

Connect With Protokinetix

Contact the team at ProtoKinetix to learn more about AAGP®’s performance in research studies.

Picture of a molecule
Picture of a molecule